We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
-11.58%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$9.66M
AUM Growth
-$1.21M
(-11%)
Cap. Flow
-$2.42M
Cap. Flow
% of AUM
-25.07%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
1
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.36M |
| 2 |
Align Technology
ALGN
|
+$351K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$1.73M |
| 2 |
Incyte
INCY
|
+$1.6M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$364K |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$258K |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$180K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.49% |
| 2 | Industrials | 7.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$1.03T
| $1.93M | 19.98% |
26,810
+17,912
| +201% | +$1.36M |
|
|
2
Edwards Lifesciences
EW
$50B
| $1.54M | 15.92% |
52,329
-62,637
| -54% | -$1.73M |
|
3
DexCom
DXCM
$28.8B
| $1.29M | 13.38% |
76,184
| – | – |
|
|
PETX
4
DELISTED
Aratana Therapeutics, Inc.
PETX
| $1.21M | 12.48% |
218,515
| – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.2M | 12.38% |
8,599
| – | – |
|
|
6
Regeneron Pharmaceuticals
REGN
$77.4B
| $826K | 8.55% |
2,291
-625
| -21% | -$258K |
|
|
ATHN
7
DELISTED
Athenahealth, Inc.
ATHN
| $680K | 7.04% |
4,900
| – | – |
|
|
8
Acadia Pharmaceuticals
ACAD
$4.55B
| $603K | 6.24% |
21,552
-8,249
| -28% | -$180K |
|
|
9
Align Technology
ALGN
$12.4B
| $390K | 4.04% |
+5,366
| New | +$351K |
|
|
10
Incyte
INCY
$24.9B
| – | – |
-14,756
| Closed | -$1.6M |
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-14,962
| Closed | -$364K |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, March Altus Capital Management held 11 positions worth $9.66M, down 11% from $10.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
March Altus Capital Management withdrew a net $2.42M in Q1 2016, closing 2 positions and reducing 3 holdings. Its most notable exit was Incyte, an estimated $1.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 78% a quarter earlier, followed by Industrials.
Against the trend, March Altus Capital Management opened a new position in Align Technology worth $390K.
- March Altus Capital Management's largest Q1 2016 buy was Align Technology: 5,366 shares worth $390K.
- March Altus Capital Management added most to Eli Lilly in Q1 2016, an estimated $1.36M increase.
- March Altus Capital Management's biggest Q1 2016 reduction was Edwards Lifesciences, cutting an estimated $1.73M.
- March Altus Capital Management fully exited Incyte in Q1 2016, selling an estimated $1.6M.
- March Altus Capital Management's ten largest holdings make up 100% of its $9.66M portfolio in Q1 2016.
- March Altus Capital Management opened 1 new position and closed 2 in Q1 2016.
- March Altus Capital Management's portfolio value fell 11% quarter-over-quarter to $9.66M.
Based on March Altus Capital Management's 13F filing for Q1 2016, filed 12 May 2016.